Evaluating brain function and psychological effects of cell therapy in autoimmune hemolytic anemia
Brain Function and Psychological Assessment in Patients With Autoimmune Hemolytic Anemia Undergoing Cell Therapy
Institute of Hematology & Blood Diseases Hospital, China · NCT06921980
This study is testing how CAR T-cell therapy affects thinking and mental health in people with autoimmune hemolytic anemia to help improve their treatment and quality of life.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 20 (estimated) |
| Ages | 18 Years to 65 Years |
| Sex | All |
| Sponsor | Institute of Hematology & Blood Diseases Hospital, China (other) |
| Drugs / interventions | CAR T |
| Locations | 1 site (Tianjin, Tianjin Municipality) |
| Trial ID | NCT06921980 on ClinicalTrials.gov |
What this trial studies
This observational study investigates the cognitive and psychological impacts of cell therapy, specifically CAR T-cell therapy, on patients diagnosed with autoimmune hemolytic anemia (AIHA). It aims to assess brain function and psychological well-being to identify potential impairments early, allowing for timely interventions. By understanding these effects, the study seeks to enhance treatment strategies and improve the overall quality of life for patients undergoing this innovative therapy.
Who should consider this trial
Good fit: Ideal candidates include adults aged 18-65 with a diagnosis of autoimmune hemolytic anemia who are set to receive cell therapy.
Not a fit: Patients with a history of psychiatric illness or severe brain disease may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to safer and more effective treatment strategies for patients with autoimmune hemolytic anemia.
How similar studies have performed: While cell therapy has shown promise in treating hematologic and autoimmune diseases, the specific focus on cognitive and psychological impacts in this context is relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Diagnosis of AIHA * Subjects will receive cell therapy such as CAR T-cell therapy * Male or female, aged 18-65 years * Willing and able to comply with the requirements for this study and written informed consent Exclusion Criteria: * History of psychiatric illness * History of severe brain disease * Subjects that the investigator believes have other reasons that make them unsuitable for inclusion in this study
Where this trial is running
Tianjin, Tianjin Municipality
- Regenerative Medicine Center — Tianjin, Tianjin Municipality, China (RECRUITING)
Study contacts
- Study coordinator: Zhexiang Kuang, MSN
- Email: kuangzhexiang@ihcams.ac.cn
- Phone: 13920361752
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: CAR T-cell Therapy, Autoimmune Hemolytic Anemia, Brain Function, Psychological Well-Being